Mylan Emerges as Leading Player in Expanding Dyspnea and Post-Herpetic Neuralgia Treatment Markets

Mylan, now part of Viatris Inc., is strategically positioning itself in the booming dyspnea and post-herpetic neuralgia markets, which are set for significant growth in the coming years. As respiratory diseases rise and pain management needs evolve, can Mylan effectively navigate the competitive landscape to enhance patient outcomes?